<DOC>
	<DOC>NCT01852045</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric patients between the ages of 5 to 17 years.</brief_summary>
	<brief_title>Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Urinary incontinence due to neurogenic detrusor overactivity Regularly using clean intermittent catheterization to empty the bladder Surgery of the spinal cord within 6 months Diagnosis of cerebral palsy Current or planned use of a baclofen pump Current or planned use of an electrostimulation/neuromodulation device for urinary incontinence Use of an indwelling catheter for urinary incontinence instead of using clean intermittent catheterization to empty the bladder Previous or current use of botulinum toxin therapy of any serotype for any urological condition, or treatment with botulinum toxin of any serotype within 3 months for any other condition or use Myasthenia gravis, EatonLambert syndrome, or amyotrophic lateral sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>